Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PRNewsWire · 4 days ago
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingPRNewsWire · 5 days ago
Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placementDefense World · Oct 10, 2026
Atrium Therapeutics Announces $50 Million Private PlacementPRNewsWire · Oct 8, 2026
Avidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?Defense World · Oct 7, 2026
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PRNewsWire · Sep 21, 2026Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.42 | -$1.18 | Beat |
| May 14, 2026 | -$1.05 | -$0.97 | Beat |
| Feb 26, 2026 | -$1.24 | -$0.61 | Beat |
| May 8, 2025 | -$0.90 | -$0.90 | Beat |
| Feb 27, 2025 | -$0.79 | -$0.80 | Miss |
| Nov 7, 2024 | -$0.71 | -$0.65 | Beat |